{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:41:25Z","timestamp":1787686885098,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10147-021-02085-6","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T12:02:43Z","timestamp":1637928163000},"page":"626-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-219X","authenticated-orcid":false,"given":"Liudmila V.","family":"Fedorova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill V.","family":"Lepik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita P.","family":"Volkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina V.","family":"Kotselyabina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia S.","family":"Borzenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina O.","family":"Popova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia V.","family":"Beynarovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim V.","family":"Baykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey V.","family":"Kozlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan S.","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia B.","family":"Mikhailova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"2085_CR1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program (2019). Cancer stat facts: Hodgkin lymphoma. SEER https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html"},{"issue":"16","key":"2085_CR2","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","volume":"117","author":"J Kuruvilla","year":"2011","unstructured":"Kuruvilla J, Keating A, Crump M (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood 117(16):4208\u20134217. https:\/\/doi.org\/10.1182\/blood-2010-09-288373","journal-title":"Blood"},{"issue":"7","key":"2085_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMra1003733","volume":"363","author":"JO Armitage","year":"2010","unstructured":"Armitage JO (2010) Early-stage Hodgkin\u2019s lymphoma. N Engl J Med 363(7):653\u2013662. https:\/\/doi.org\/10.1056\/NEJMra1003733","journal-title":"N Engl J Med"},{"key":"2085_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.497","author":"J Kuruvilla","year":"2009","unstructured":"Kuruvilla J (2009) Standard therapy of advanced Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. https:\/\/doi.org\/10.1182\/asheducation-2009.1.497","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2085_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.222","author":"M Andre\u2019","year":"1999","unstructured":"Andre\u2019 M, Henry-Amar M, Pico JL et al (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin\u2019s disease induction failure: a case-control study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.1999.17.1.222","journal-title":"J Clin Oncol"},{"issue":"8852","key":"2085_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-l","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet 341(8852):1051\u20131054. https:\/\/doi.org\/10.1016\/0140-6736(93)92411-l","journal-title":"Lancet"},{"issue":"9323","key":"2085_CR7","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 359(9323):2065\u20132071. https:\/\/doi.org\/10.1016\/S0140-6736(02)08938-9","journal-title":"Lancet"},{"key":"2085_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdi003","volume":"16","author":"A Josting","year":"2005","unstructured":"Josting A, Rudolph C, Mapara M et al (2005) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16:116\u2013123. https:\/\/doi.org\/10.1093\/annonc\/mdi003","journal-title":"Ann Oncol"},{"key":"2085_CR9","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1172\/JCI95993","volume":"128","author":"MA Weniger","year":"2018","unstructured":"Weniger MA, Tiacci E, Schneider S et al (2018) Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells. J Clin Investig 128:2996\u20133007. https:\/\/doi.org\/10.1172\/JCI95993","journal-title":"J Clin Investig"},{"key":"2085_CR10","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","volume":"130","author":"CD Carey","year":"2017","unstructured":"Carey CD, Gusenleitner D, Lipschitz M et al (2017) Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420\u20132430. https:\/\/doi.org\/10.1182\/blood-2017-03-770719","journal-title":"Blood"},{"issue":"10","key":"2085_CR11","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1080\/10428194.2017.1300898","volume":"58","author":"S Borchmann","year":"2017","unstructured":"Borchmann S, von Tresckow B (2017) Novel agents in classical Hodgkin lymphoma. Leuk Lymphoma 58(10):2275\u20132286. https:\/\/doi.org\/10.1080\/10428194.2017.1300898","journal-title":"Leuk Lymphoma"},{"key":"2085_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/joim.12582","volume":"281","author":"I Glimelius","year":"2017","unstructured":"Glimelius I, Diepstra A (2017) Novel treatment concepts in Hodgkin lymphoma. J Intern Med 281:247\u2013260. https:\/\/doi.org\/10.1111\/joim.12582","journal-title":"J Intern Med"},{"key":"2085_CR13","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-2469","author":"SJ Gardai","year":"2015","unstructured":"Gardai SJ, Epp A, Law C-L (2015) Brentuximab vedotin-mediated immunogenic cell death. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-2469","journal-title":"Cancer Res"},{"key":"2085_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-4914","author":"A Cao","year":"2016","unstructured":"Cao A, Heiser R, Law CL et al (2016) Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.AM2016-4914","journal-title":"Cancer Res"},{"issue":"18","key":"2085_CR15","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183\u20132189. https:\/\/doi.org\/10.1200\/JCO.2011.38.0410","journal-title":"J Clin Oncol"},{"issue":"12","key":"2085_CR16","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE et al (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128(12):1562\u20131566. https:\/\/doi.org\/10.1182\/blood-2016-02-699850","journal-title":"Blood"},{"issue":"4","key":"2085_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"2085_CR18","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428\u20131439. https:\/\/doi.org\/10.1200\/JCO.2017.76.0793","journal-title":"J Clin Oncol"},{"issue":"19","key":"2085_CR19","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA et al (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125\u20132132. https:\/\/doi.org\/10.1200\/JCO.2016.72.1316","journal-title":"J Clin Oncol"},{"issue":"9","key":"2085_CR20","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1080\/10428194.2019.1573368","volume":"60","author":"KV Lepik","year":"2019","unstructured":"Lepik KV, Mikhailova NB, Moiseev IS et al (2019) Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT\u00adna\u00efve patients. Leuk Lymphoma 60(9):2316\u20132319. https:\/\/doi.org\/10.1080\/10428194.2019.1573368","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2085_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.18620\/ctt-1866-8836-2019-8-4-41-48","volume":"8","author":"AV Kozlov","year":"2019","unstructured":"Kozlov AV, Kazantzev IV, Iukhta TV et al (2019) Nivolumab in pediatric Hodgkin\u2019s lymphoma. Cell Ther Transplant 8(4):41\u201348. https:\/\/doi.org\/10.18620\/ctt-1866-8836-2019-8-4-41-48","journal-title":"Cell Ther Transplant"},{"issue":"2","key":"2085_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda A, Canals C, Arranz R et al (2012) Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2014a prospective clinical trial by the grupo espa\u00f1ol de linfomas\/trasplante de m\u00e9dula osea. Haematologica 97(2):310\u2013317. https:\/\/doi.org\/10.3324\/haematol.2011.045757","journal-title":"Haematologica"},{"issue":"32","key":"2085_CR23","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW et al (2020) Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 38(32):3794\u20133804. https:\/\/doi.org\/10.1200\/JCO.20.01342","journal-title":"J Clin Oncol"},{"key":"2085_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000401","author":"KV Lepik","year":"2020","unstructured":"Lepik KV, Mikhailova KV, Kondakova EV et al (2020) A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed\/refractory Hodgkin lymphoma after nivolumab monotherapy failure. Hemasphere. https:\/\/doi.org\/10.1097\/HS9.0000000000000401","journal-title":"Hemasphere"},{"issue":"8","key":"2085_CR25","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ajh.25154","volume":"93","author":"C Rossi","year":"2018","unstructured":"Rossi C, Gilhodes J, Maerevoet M et al (2018) Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from LYSA centers. Am J Hematol 93(8):1042\u20131049. https:\/\/doi.org\/10.1002\/ajh.25154","journal-title":"Am J Hematol"},{"issue":"1","key":"2085_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A et al (2018) Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 132(1):40\u201348. https:\/\/doi.org\/10.1182\/blood-2017-11-815183","journal-title":"Blood"},{"issue":"12","key":"2085_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41408-019-0265-x","volume":"9","author":"A Broccoli","year":"2019","unstructured":"Broccoli A, Argnani L, Botto B et al (2019) First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer J 9(12):100. https:\/\/doi.org\/10.1038\/s41408-019-0265-x","journal-title":"Blood Cancer J"},{"key":"2085_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1758835918762094","volume":"10","author":"C Lazzari","year":"2018","unstructured":"Lazzari C, Karachaliou N, Bulotta A et al (2018) Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? Ther Adv Med Oncol 10:1\u201312. https:\/\/doi.org\/10.1177\/1758835918762094","journal-title":"Ther Adv Med Oncol"},{"key":"2085_CR29","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","volume":"75","author":"J Peng","year":"2015","unstructured":"Peng J, Hamanishi J, Matsumura N et al (2015) Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 75:5034\u20135045. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3098","journal-title":"Cancer Res"},{"key":"2085_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"Liu WM, Fowler DW, Smith P et al (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102:115\u2013123. https:\/\/doi.org\/10.1038\/sj.bjc.6605465","journal-title":"Br J Cancer"},{"key":"2085_CR31","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.4049\/jimmunol.1202005","volume":"190","author":"TJ Kearl","year":"2013","unstructured":"Kearl TJ, Jing W, Gershan JA et al (2013) Programmed death receptor-1\/ programmed death receptor ligand-1 blockade after transient lympho-depletion to treat myeloma. J Immunol 190:5620\u20135628. https:\/\/doi.org\/10.4049\/jimmunol.1202005","journal-title":"J Immunol"},{"issue":"11","key":"2085_CR32","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL et al (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131(11):1183\u20131194. https:\/\/doi.org\/10.1182\/blood-2017-10-811224","journal-title":"Blood"},{"issue":"Suppl. 1","key":"2085_CR33","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2018-99-110002","volume":"132","author":"RH Advani","year":"2018","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL et al (2018) Phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory classic Hodgkin lymphoma: part 3 (concurrent dosing) results and updated progression-free survival results from parts 1 and 2 (staggered dosing). Blood 132(Suppl. 1):1635. https:\/\/doi.org\/10.1182\/blood-2018-99-110002","journal-title":"Blood"},{"key":"2085_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/hon.2437_72","volume":"35","author":"CS Diefenbach","year":"2017","unstructured":"Diefenbach CS, Hong F, David K et al (2017) Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412). Hematol Oncol 35:84\u201385. https:\/\/doi.org\/10.1002\/hon.2437_72","journal-title":"Hematol Oncol"},{"key":"2085_CR35","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1182\/blood.V128.22.1106.1106","volume":"128","author":"CS Diefenbach","year":"2016","unstructured":"Diefenbach CS, Hong F, David KA et al (2016) Title: a phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412 Arms D and E). Blood 128:1106. https:\/\/doi.org\/10.1182\/blood.V128.22.1106.1106","journal-title":"Blood"},{"key":"2085_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hon.83_2629","volume":"37","author":"CS Diefenbach","year":"2019","unstructured":"Diefenbach CS, Hong F, Ambinder R et al (2019) Extended follow-up of a phase I trial of ipilimumab, nivolumab and brentuximab vedotin in relapsed Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412). Hematol Oncol 37:123\u2013124. https:\/\/doi.org\/10.1002\/hon.83_2629","journal-title":"Hematol Oncol"},{"key":"2085_CR37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/blood.V126.23.585.585","volume":"126","author":"CS Diefenbach","year":"2015","unstructured":"Diefenbach CS, Hong F, Cohen JB et al (2015) Preliminary safety and efficacy of the combination of brentuximab vedotin and ipilimumab in relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412). Blood 126:585. https:\/\/doi.org\/10.1182\/blood.V126.23.585.585","journal-title":"Blood"},{"key":"2085_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000480","author":"KV Lepik","year":"2020","unstructured":"Lepik KV, Fedorova LV, Kondakova EV et al (2020) A phase 2 study of nivolumab using a fixed dose of 40mg (Nivo40) in patients with relapsed\/ refractory Hodgkin lymphoma. Hemasphere. https:\/\/doi.org\/10.1097\/HS9.0000000000000480","journal-title":"Hemasphere"},{"issue":"9","key":"2085_CR39","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","volume":"7","author":"CS Diefenbach","year":"2020","unstructured":"Diefenbach CS, Hong F, Ambinder RF et al (2020) Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial. Lancet Haematol 7(9):e660\u2013e670. https:\/\/doi.org\/10.1016\/S2352-3026(20)30221-0","journal-title":"Lancet Haematol"},{"key":"2085_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0177-2","author":"S Agrawal","year":"2016","unstructured":"Agrawal S, Feng Y, Roy A et al (2016) Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-016-0177-2","journal-title":"J Immunother Cancer"},{"key":"2085_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/psp4.12133","volume":"6","author":"X Wang","year":"2017","unstructured":"Wang X, Feng Y, Bajaj G et al (2017) Quantitative characterization of the exposure-response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma. CPT Pharmacometr Syst Pharmacol 6:40\u201348","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"2085_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1654100","author":"N Fukuharaa","year":"2019","unstructured":"Fukuharaa N, Yamamotob G, Tsujimurac H et al (2019) Retreatment with brentuximab vedotin in patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma. https:\/\/doi.org\/10.1080\/10428194.2019.1654100","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2085_CR43","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-02085-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:20:25Z","timestamp":1744194025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-02085-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2085"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-02085-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the 1964 Helsinki declaration and approved by the institutional review board. All enrolled patients gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}